Delirium is one of the most common and devastating neuropsychiatric syndromes in patients with advanced illnesses. It negatively impacts every aspect of patient care, including symptom expression, patient-clinician communication, decision-making, family relationships, and survival. 1 However, there is a paucity of studies on the management of delirium, particularly in the palliative care setting. It is thus encouraging to see two systematic reviews on this important topic in recent issues of the Journal. 2, 3 Delirium as a syndrome is characterized by a common set of symptoms and is often discussed as if it is a single entity; however, it is critical to note that there are many delirium subtypes. Delirium in different patient populations and settings has different prevalence, causes, natural history, and outcomes. For example, post-operative delirium is distinct from delirium in hospitalized patients admitted to medical wards. Even among patients seen by palliative care, delirium is highly heterogeneous. Patients at long-term care facilitates who developed delirium on a background of dementia, those admitted to intensive care units for heart failure exacerbation complicated by delirium, and cancer patients who were imminently dying with terminal delirium at palliative care units had different causes of delirium and outcomes. Thus, identification of the etiology of delirium is essential to guide proper management. Indeed, treatment of the underlying cause(s) remains the only established strategy to reverse some types of delirium. 4 Recognition of the context and prognosis of the patient is also important for setting the goals of care and expectations.
Watt et al. 2 provided a comprehensive update of a previous systematic review to examine the prevalence of delirium in palliative care. Based on 42 studies, the investigators highlighted the overall high prevalence of delirium (35%), supporting the need to implement systematic delirium screening in most palliative care settings. Importantly, the point prevalence estimates varied widely, ranging from 4% to 12% in the community, 9%-57% for patients seen by hospital palliative care consultative services, and 6%-74% in inpatient palliative care units. This wide variation is likely related to heterogeneity in both the patient populations and assessment methods. Their findings underscore that palliative care patients are not all the same, and we need to personalize our approach to delirium screening and management.
In the second systematic review, Hosie et al. 3 assessed how often studies on non-pharmacological interventions for delirium included patients requiring palliative care based on the Gold Standards Framework. Among the 29 included studies, only one specifically enrolled patients from the palliative care unit and found that non-pharmacological interventions did not prevent delirium. Although 26 other studies might have included some patients requiring palliative care, it was difficult to know how generalizable were the study findings. Unfortunately, the lack of clear description of patient characteristics is a common concern in the literature that can significantly complicate data intepretation. 5 This meticulous systematic review highlights the need to clearly describe the study population. Given the lack of good evidence in patients requiring palliative care, should we consider non-pharmacological interventions? I believe it is still reasonable to implement these measures when appropriate, since interventions to prevent dehydration, promote early ambulation, and enhance orientation likely have low risk of harm and could provide meaningful benefits regardless of delirium. One would hypothesize that non-pharmacologic interventions could be effective for prevention of delirium in geriatric patients seen by inpatient palliative care consultation teams but may be less useful for delirium in patients in the last days of life.
The principle of sorting out delirium subtypes applies to pharmacologic therapies as well. For example, benzodiazepines have a well-established role in the treatment of delirium tremens and may be considered for patients with persistent agitation in the terminal delirium setting; 6 however, they should generally be avoided in other settings. Similarly, neuroleptics may still have a role for specific delirium outcomes (e.g. control of agitation) in specific groups of patients, although there remains much confusion about their risks and benefits. This confusion is partly because some original studies and systematic reviews have mixed heterogeneous patient populations and subtypes together. 7 This problem is further compounded by the lack of adequate description of study participants in some papers.
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As Einstein said, "The world as we have created is a process of our thinking. It cannot be changed without changing our thinking." Moving forward, we need to rethink and refine our approach to conducting delirium research. We do not just need more original studies on delirium, but these studies should target specific delirium subtypes based on etiologies, settings, and prognosis. A better fundamental understanding of the pathophysiology of delirium subtypes could transform how we classify and treat delirium. When designing clinical studies, research questions should be focused, and eligibility criteria should be clearly defined. Because palliative care services are now offered throughout the disease continuum in many settings, 8 studies examining "palliative care" patients need to be particularly careful in distinguishing the different delirium subtypes being included and conduct subgroup analysis if appropriate. Indeed, a clearly defined study population could help tailor the study interventions and outcomes. For instance, in the terminal delirium setting, palliation is a much more realistic outcome than reversal. In addition, a clear description of eligibility criteria and patient and delirium characteristics is essential for readers to assess the generalizability of study findings. By sorting out the various delirium subtypes, investigators can help bring more clarity to the literature and allow clinicians to manage this challenging syndrome with much more sophistication.
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